BioLargo (NASDAQ:BLGO – Get Free Report) is one of 33 public companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its competitors? We will compare BioLargo to similar companies based on the strength of its institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and earnings.
Volatility & Risk
BioLargo has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.81, suggesting that their average stock price is 81% more volatile than the S&P 500.
Valuation and Earnings
This table compares BioLargo and its competitors top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -8.00 |
BioLargo Competitors | $6.84 billion | $211.64 million | 66.85 |
Institutional & Insider Ownership
0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -591.84% | 5.15% | -0.65% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for BioLargo and its competitors, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1250 | 1568 | 44 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 15.66%. Given BioLargo’s competitors higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its competitors.
Summary
BioLargo competitors beat BioLargo on 8 of the 10 factors compared.
BioLargo Company Profile
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.